Literature DB >> 25451693

Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database.

Lauren S Prescott1, Thomas A Aloia2, Alaina J Brown3, Jolyn S Taylor3, Mark F Munsell4, Charlotte C Sun3, Kathleen M Schmeler3, Charles F Levenback3, Diane C Bodurka3.   

Abstract

OBJECTIVE: To use a large-scale multi-institutional dataset to quantify the prevalence of packed red blood cell transfusions and examine the associations between transfusion and perioperative outcomes in gynecologic cancer surgery.
METHODS: The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) participant use file was queried for all gynecologic cancer cases between 2010 and 2012. Demographic, preoperative and intraoperative variables were compared between transfusion and non-transfusion groups using chi-squared, Fisher's exact and Wilcoxon rank-sum tests. The primary endpoint was 30-day composite morbidity. Secondary endpoints included composite surgical site infections, mortality and length of stay.
RESULTS: A total of 8519 patients were analyzed, and 13.8% received a packed red blood cell transfusion. In the multivariate analysis, after adjusting for key clinical and perioperative factors, including preoperative anemia and case magnitude, transfusion was associated with higher composite morbidity (OR = 1.85, 95% CI 1.5-2.24), surgical site infections (OR 1.80, 95% CI 1.39-2.35), mortality (OR 3.38, 95% CI 1.80-6.36) and length of hospital stay (3.02 days v. 7.17 days, P < 0.001).
CONCLUSIONS: Blood transfusions are associated with increased surgical wound infections, composite morbidity and mortality. Based on our analysis of the NSQIP database, transfusion practices in gynecologic cancer should be scrutinized. Examination of institutional practices and creation of transfusion guidelines for gynecologic malignancies could potentially result in better utilization of blood bank resources and clinical outcomes among patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blood utilization; Gynecologic oncology; NSQIP; Perioperative outcomes; Transfusion

Mesh:

Year:  2014        PMID: 25451693      PMCID: PMC4492800          DOI: 10.1016/j.ygyno.2014.11.009

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

Review 1.  Mechanisms and new approaches for the allogeneic blood transfusion-induced immunomodulatory effects.

Authors:  K J Kao
Journal:  Transfus Med Rev       Date:  2000-01

2.  The influence of peri-operative blood transfusion during radical hysterectomy on the prognosis of uterine cervical cancer.

Authors:  C Azuma; M Koyama; M Inagaki; S Ito; M Sawada; F Saji; M Ozaki
Journal:  Transfus Sci       Date:  1997-03

3.  THE INFLUENCE OF ANEMIA ON THE RESULTS OF RADIOTHERAPY IN CARCINOMA OF THE CERVIX.

Authors:  J C EVANS; P BERGSJO
Journal:  Radiology       Date:  1965-04       Impact factor: 11.105

4.  A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

Authors:  P C Hébert; G Wells; M A Blajchman; J Marshall; C Martin; G Pagliarello; M Tweeddale; I Schweitzer; E Yetisir
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

Review 5.  Anemia, hypoxia and transfusion in patients with cervix cancer: a review.

Authors:  A W Fyles; M Milosevic; M Pintilie; A Syed; R P Hill
Journal:  Radiother Oncol       Date:  2000-10       Impact factor: 6.280

6.  Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival.

Authors:  Nadeem R Abu-Rustum; Scott Richard; Andrew Wilton; Gali Lev; Yukio Sonoda; Martee L Hensley; Mary Gemignani; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2005-08-02       Impact factor: 5.482

7.  Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis.

Authors:  Juergen Dunst; Thomas Kuhnt; Hans G Strauss; Ulf Krause; Tanja Pelz; Heinz Koelbl; Gabriele Haensgen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

Review 8.  Transfusion and recipient immune function.

Authors:  N Blumberg; J M Heal
Journal:  Arch Pathol Lab Med       Date:  1989-03       Impact factor: 5.534

9.  Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  Nick M Spirtos; Cynthia M Westby; Hervy E Averette; John T Soper
Journal:  Am J Clin Oncol       Date:  2002-08       Impact factor: 2.339

Review 10.  Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?

Authors:  Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2004-11       Impact factor: 3.621

View more
  14 in total

Review 1.  Indications for and complications of transfusion and the management of gynecologic malignancies.

Authors:  Paulina Cybulska; Cheryl Goss; William P Tew; Rekha Parameswaran; Yukio Sonoda
Journal:  Gynecol Oncol       Date:  2017-05-18       Impact factor: 5.482

2.  Improvement of Perioperative Outcomes in Major Gynecological and Gynecologic-Oncological Surgery with Hemostatic Gelatin-Thrombin Matrix.

Authors:  Rafał Watrowski; Christoph Jäger; Johannes Forster
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

3.  Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology.

Authors:  Lauren S Prescott; Jolyn S Taylor; Ahmed Enbaya; Claire A Marten; Keith N Myers; Larissa A Meyer; Pedro T Ramirez; Charles F Levenback; Diane C Bodurka; Kathleen M Schmeler
Journal:  Gynecol Oncol       Date:  2019-03-11       Impact factor: 5.482

4.  Peri-operative blood management of Jehovah's Witnesses undergoing cytoreductive surgery for advanced ovarian cancer.

Authors:  Innocenza Palaia; Giuseppe Caruso; Violante Di Donato; Giorgia Perniola; Giancarlo Ferrazza; Enrico Panzini; Maria Scudo; Anna Di Pinto; Ludovico Muzii; Pierluigi Benedetti Panici
Journal:  Blood Transfus       Date:  2021-02-25       Impact factor: 3.443

5.  Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.

Authors:  Akshat Saxena; Sarah J Valle; Winston Liauw; David L Morris
Journal:  J Gastrointest Surg       Date:  2017-05-30       Impact factor: 3.452

Review 6.  How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology.

Authors:  Lauren S Prescott; Jolyn S Taylor; Maria A Lopez-Olivo; Mark F Munsell; Helena M VonVille; David R Lairson; Diane C Bodurka
Journal:  Cancer Treat Rev       Date:  2016-03-28       Impact factor: 12.111

7.  Implementation of a restrictive blood transfusion protocol in a gynecologic oncology service.

Authors:  Jaron Mark; Sarah Lynam; Kayla Morrell; Kevin Eng; Kristen Starbuck; J Brian Szender; Emese Zsiros; Peter J Frederick
Journal:  Gynecol Reprod Endocrinol       Date:  2019

8.  Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study.

Authors:  Mette Ørskov; Maria Iachina; Rikke Guldberg; Ole Mogensen; Bente Mertz Nørgård
Journal:  BMJ Open       Date:  2016-04-21       Impact factor: 2.692

9.  Perioperative blood transfusion is associated with post-operative infectious complications in patients with Crohn's disease.

Authors:  Nan Lan; Luca Stocchi; Yi Li; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-05-30

10.  Which patients on a gynecologic oncology service will require perioperative transfusion? A single-center retrospective cohort study.

Authors:  Gregory W Kirschen; Samantha M Dayton; Sophia Blakey-Cheung; Michael L Pearl
Journal:  Clin Exp Obstet Gynecol       Date:  2021-02-15       Impact factor: 0.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.